Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Interparfums reports Q1 2026 sales of $345M, EPS $1.35, and confirms full-year guidance with a June dividend.

Company Fundamentals
05 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Interparfums, Inc. announced Q1 2026 net sales of $345 million, a 2% increase from last year, with diluted EPS rising to $1.35. The company saw strong growth in North America and Central/South America, driven by key brands like Coach and Montblanc, despite challenges in Eastern Europe and Asia-Pacific. Gross margin improved to 65.1%, and the company reaffirmed its 2026 full-year guidance of $1.48 billion in sales and $4.85 EPS. A quarterly dividend of $0.80 per share will be paid on June 30, 2026, reflecting confidence in ongoing growth and financial stability.

More News

Class action filed against Nano-X for alleged securities fraud, investors urged to join by Aug 11, 2026.

Class action filed against Nano-X for alleged securities fraud, investors urged to join by Aug 11, 2026.

A class action lawsuit has been filed against Nano-X Imaging Ltd. and some of its officers, accusing them of making false and misleading statements about the company's operations and prospects between March 31, 2025, and April 17, 2026. The lawsuit c...

Market News
Bearish
50 minutes ago
Osteoarthritis market to grow 3% CAGR through 2036, fueled by new therapies and rising disease cases

Osteoarthritis market to grow 3% CAGR through 2036, fueled by new therapies and rising disease cases

The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...

Market News
Bullish
50 minutes ago
Rhythm Pharma shares rise after positive 6-month data on obesity drug setmelanotide in Prader-Willi syndrome patients.

Rhythm Pharma shares rise after positive 6-month data on obesity drug setmelanotide in Prader-Willi syndrome patients.

Rhythm Pharmaceuticals reported encouraging six-month Phase 2 trial results for setmelanotide in patients with Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and behavior. The study involved 18 patients aged 6 to 2...

Company Fundamentals
Bullish
58 minutes ago
FDA approves AstraZeneca's Truqap for targeted prostate cancer treatment; Ultomiris gets Priority Review for kidney disease.

FDA approves AstraZeneca's Truqap for targeted prostate cancer treatment; Ultomiris gets Priority Review for kidney disease.

AstraZeneca received FDA approval for Truqap (capivasertib) combined with abiraterone and prednisone to treat PTEN-deficient metastatic prostate cancer, marking the first targeted therapy for this group. The approval was based on Phase III trial data...

Market News
Bullish
59 minutes ago
TripAdvisor sells TheFork to American Express for $700M, boosting capital return plans.

TripAdvisor sells TheFork to American Express for $700M, boosting capital return plans.

TripAdvisor has agreed to sell its European restaurant reservation platform, TheFork, to American Express for $700 million in cash. TheFork generated $232 million in revenue and $28 million in adjusted EBITDA in the past year. This sale supports Trip...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App